Compare

Aclaris Therapeutics, Inc. vs Whitehawk Therapeutics, Inc. vs International Stem Cell Corp vs Jaguar Health, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Aclaris Therapeutics, Inc. ACRS	Whitehawk Therapeutics, Inc. WHWK	International Stem Cell Corp ISCO	Jaguar Health, Inc. JAGX
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$7.83M	$7.14M	$9.10M	$11.51M
Revenue growth (YoY)	-58.2%	-72.5%	+0.2%	-1.5%
Gross margin	73.3% (computed)	89.4% (computed)	55.7% (computed)	67.2% (computed)
Operating margin	-975.9%	n/m	-2.9%	-398.8%
Net margin	-829.6%	-288.3%	-4.6%	-465.4%
Net income	-$64.92M	-$20.60M	-$418.0K	-$53.58M
EPS (Diluted)	-$0.53	-$0.33	-$0.05	-$22.97
Operating cash flow	-$47.11M	-$97.43M	$8.0K	-$23.69M
Free cash flow	-$47.22M	-$97.98M	-$35.0K	n/a
Cash & equivalents	$19.96M	$37.57M	n/a	$968.0K
Total assets	$160.46M	$150.83M	$4.82M	$38.32M
Total liabilities	$57.38M	$14.52M	$4.58M	$57.01M
Shareholders' equity	$103.08M	$136.31M	-$4.06M	-$18.69M
Return on year-end equity	-63.0%	-15.1%	n/a	n/a
Shares outstanding	120.50M	47.15M	8.00M	n/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Aclaris Therapeutics, Inc.	Whitehawk Therapeutics, Inc.	International Stem Cell Corp	Jaguar Health, Inc.
Latest	$7.83M Ended 2025-12-31	$7.14M Ended 2025-12-31	$9.10M Ended 2025-12-31	$11.51M Ended 2025-12-31
1 year earlier	$18.72M Ended 2024-12-31	$25.98M Ended 2024-12-31	$9.09M Ended 2024-12-31	$11.69M Ended 2024-12-31
2 years earlier	$31.25M Ended 2023-12-31	$24.35M Ended 2023-12-31	$7.79M Ended 2023-12-31	$9.76M Ended 2023-12-31
3 years earlier	$29.75M Ended 2022-12-31	$15.22M Ended 2022-12-31	$8.18M Ended 2022-12-31	$11.96M Ended 2022-12-31
4 years earlier	$6.76M Ended 2021-12-31	$14.00M Ended 2021-12-31	$7.18M Ended 2021-12-31	$4.33M Ended 2021-12-31